These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 30845112)

  • 1. Is 50 mg/day the new standard dose of dasatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase?
    Saydan B; Özmen D; Eşkazan AE
    Expert Rev Hematol; 2024 Jul; 17(7):275-277. PubMed ID: 38888284
    [No Abstract]   [Full Text] [Related]  

  • 2. Chronic myeloid leukemia: room for improvement?
    Baccarani M; Pane F; Rosti G; Russo D; Saglio G
    Haematologica; 2017 Jul; 102(7):1131-1133. PubMed ID: 28655808
    [No Abstract]   [Full Text] [Related]  

  • 3. Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice.
    Clark RE
    Curr Hematol Malig Rep; 2019 Dec; 14(6):507-514. PubMed ID: 31701369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms.
    Mughal TI; Abdel-Wahab O; Rampal R; Mesa R; Koschmieder S; Levine R; Hehlmann R; Saglio G; Barbui T; Van Etten RA
    Leuk Lymphoma; 2016 Jul; 57(7):1517-26. PubMed ID: 27240645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asciminib is safe and effective in patients with newly diagnosed CML.
    Romero D
    Nat Rev Clin Oncol; 2024 Aug; 21(8):566. PubMed ID: 38918596
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment discontinuation in chronic myeloid leukemia: When, how, and why?
    Haddad FG; Short NJ
    Am J Hematol; 2023 Nov; 98(11):1670-1672. PubMed ID: 37753704
    [No Abstract]   [Full Text] [Related]  

  • 7. Data Resource Profile: The Systemic Anti-Cancer Therapy (SACT) dataset.
    Bright CJ; Lawton S; Benson S; Bomb M; Dodwell D; Henson KE; McPhail S; Miller L; Rashbass J; Turnbull A; Smittenaar R
    Int J Epidemiol; 2020 Feb; 49(1):15-15l. PubMed ID: 31340008
    [No Abstract]   [Full Text] [Related]  

  • 8. Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.
    Bhalla S; Tremblay D; Mascarenhas J
    Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):488-494. PubMed ID: 27406834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. When can tyrosine kinase inhibitors be discontinued in patients with chronic myeloid leukemia?
    Mahon FX
    Clin Adv Hematol Oncol; 2019 Feb; 17(2):101-103. PubMed ID: 30845112
    [No Abstract]   [Full Text] [Related]  

  • 10. Present results and future perspectives in optimizing chronic myeloid leukemia therapy.
    Carella AM; Saglio G; Mahon XF; Mauro MJ
    Haematologica; 2018 Jun; 103(6):928-930. PubMed ID: 29866888
    [No Abstract]   [Full Text] [Related]  

  • 11. Towards a Personalized Treatment of Patients with Chronic Myeloid Leukemia.
    Rabian F; Lengline E; Rea D
    Curr Hematol Malig Rep; 2019 Dec; 14(6):492-500. PubMed ID: 31760572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia.
    Mathisen MS; Kantarjian HM; Cortes J; Jabbour EJ
    Blood Rev; 2014 Sep; 28(5):179-87. PubMed ID: 24984571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of hepatitis B reactivation under treatment with tyrosine-kinase inhibitors for chronic myeloid leukemia.
    Orlandi EM; Elena C; Bono E
    Leuk Lymphoma; 2017 Jul; 58(7):1764-1766. PubMed ID: 27892750
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.